A carregar...
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis
Molecular characterization of Philadelphia chromosome-negative (Ph−) chronic myeloproliferative disorders, such as systemic mastocytosis (SM), has provided a clear rationale for investigating novel targeted therapies. The tyrosine kinase (TK) inhibitor dasatinib is 325-fold more potent against Bcr-A...
Na minha lista:
| Publicado no: | Clin Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2008
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5018899/ https://ncbi.nlm.nih.gov/pubmed/18559612 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-08-0366 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|